Subtyping colorectal cancer
Kyoto UniversityPeer-Reviewed Publication
Kyoto, Japan -- Colorectal cancer, or CRC, is the world's second most lethal cancer based on the number of deaths, and is the third most prevalent malignant tumor. Doctors and patients have long been hoping for better diagnostics for prognosis, such as molecular subtyping, which uses data collected from cancer stem cells, or tumor-initiating cells, to further divide one type of cancer into subgroups. It may correlate with patient outcomes and enable better prognoses.
Though many CRC tissue samples have been analyzed and classified based on mRNA gene expression, currently the practical application of these studies in patient prognosis is limited for colorectal cancer. This motivated a team of researchers from Kyoto University to examine cancer stem cells for the molecular subtyping of CRC.
"We need more comprehensive and clinically useful markers and their signatures to help predict the outcome of each patient," says first author Fumihiko Kakizaki.
- Journal
- Cancer Science
- Funder
- Japan Society for the Promotion of Science, Japan Science and Technology Agency, Japan Agency for Medical Research and Development